AlloMune system

AlloMune™ system

A proprietary system designed to re-educate a recipient's immune system to accept a transplanted organ as its own, which is based on transplanting bone marrow (BM) from donor to recipient to establish mixed BM chimerism, allowing the recipient's body to recognise a donor organ as its own without needing long-term anti-rejection therapy.

The AlloMune system included conditioning of the recipient and treatment with MEDI-507 and enriched peripheral blood progenitor cells; post-transplant, patients are placed on short-term immunosuppressive therapy.
References in periodicals archive ?
The Company's assets also include its AlloMune System technologies, which are intended to treat a variety of hematologic malignancies and improve outcomes for solid organ transplants.
Revamped AlloMune System Development Strategy: The company revised its clinical development strategy for the AlloMune System and will now employ kits consisting of BioTransplant's proprietary antibody MEDI-507, also known as siplizumab, in combination with products that have already been approved in the United States.
In late July BioTransplant announced it was implementing a restructuring plan intended to streamline the company's operations around its most promising proprietary products-the Allomune System and Eligix HDM Cell Separation technologies.
In the studies, miniature swine received a prototype of BioTransplant's AlloMune System and a 30 to 60 day course of cyclosporin as conditioning for a high-dose peripheral blood stem cell (PBSC) transplant from haploidentical donors.
The Company's AlloMune System is being developed to treat a variety of hematologic malignancies and solid organ transplants, and the Company has approval to market three of its Eligix HDM Cell Separation Systems in Europe.
The Company's assets also include the AlloMune System technologies, which are intended to treat a variety of hematologic malignancies and improve outcomes for solid organ transplants.
BioTransplant says it is targeting the use of the Eligix Cell Separation products as a component of the AlloMune System, which, along with its proprietary monoclonal antibody MEDI-507, is being developed as a complete approach to increase the safety and efficacy of immune modulation and transplantation for cancer and other life threatening diseases.
The Company's assets also include the AlloMune System technologies, which are intended to treat a variety of hematologic malignancies and improve outcomes for solid organ transplants, and the Eligix HDM Cell Separation Systems, which use monoclonal antibodies to remove unwanted cells from bone marrow, peripheral blood stem cell and donor leukocyte grafts used in transplant procedures.
The AlloMune System is designed to allow long-term organ acceptance without the use of chronic immunosuppressive drugs.
In addition, the Company is developing the AlloMune System, which is designed to treat a variety of hematologic malignancies, and its distribution partner Gambro BCT markets the Eligix family of cell separation products in Europe for use in bone marrow, stem cell and donor leukocyte transplants.
In addition, the Company is developing the AlloMune System, which is designed to treat a variety of hematologic malignancies, and its distribution partner, Gambro BCT, markets the Eligix family of cell separation products in Europe for use in bone marrow, stem cell and donor leukocyte transplants.
This news release contains forward-looking statements about BioTransplant that involve risks and uncertainties, including, without limitation, statements relating to the Company's expected revenues (including product revenue) for 2002, the implementation of the Company's restructuring plan, the Company's receipt of certain milestone payments, the ability of the Company to accelerate Eligix(TM) product sales, the ability of the Company to revise its clinical development strategy for its AlloMune System, and the availability of cash.